Skip to main content
Evidence Snapshot

Tyrosine-protein kinase BTK

CHEMBL5251 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:41:48Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5251
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase BTK as ChEMBL target CHEMBL5251, mapped to UniProt Q06187. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein kinase BTK
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5251
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q06187
Tyrosine-protein kinase BTK
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Tyrosine-protein kinase BTK matters

As of 2026-09-13

Tyrosine-protein kinase BTK is reviewed as Tyrosine-protein kinase BTK (UniProt Q06187); Tyrosine-protein kinase BTK shows approved-linked disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block.; 8 linked drugs keep this evidence frame grounded.; the current evidence base includes 33 approved drugs, 14839 compounds, and 1626 assays, with lead potency reaching pChEMBL 10.8.

Disease context
chronic lymphocytic leukemia

Tyrosine-protein kinase BTK shows approved-linked disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ACALABRUTINIB, ACALABRUTINIB MALEATE, EDRALBRUTINIB.

Start review with chronic lymphocytic leukemia because it currently carries approved-linked support. Linked drugs include ACALABRUTINIB, ACALABRUTINIB MALEATE, EDRALBRUTINIB, IBRUTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 8 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 33 approved drugs, 14839 compounds, and 1626 assays for this target. The dominant activity type is IC50. CHEMBL4762397 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL4762397 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine
33 approved pChEMBL 10.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Tyrosine-protein kinase BTK matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q06187, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why chronic lymphocytic leukemia is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

14839
Total Compounds
1626
Total Assays
33
Approved Drugs
IC50: 21606.0, KI: 1013.0, EC50: 733.0, KD: 443.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4762397
 10.8 IC50 —
No preferred name
CHEMBL5977366
 10.5 IC50 —
No preferred name
CHEMBL5945342
 10.4 IC50 —
No preferred name
CHEMBL5826570
 10.4 IC50 —
No preferred name
CHEMBL5884405
 10.3 IC50 —

Approved Drugs

Structure Compound First Approval
RITLECITINIB
CHEMBL4085457
 2023
FUTIBATINIB
CHEMBL3701238
 2022
TIRABRUTINIB
CHEMBL4071161
 2020
FEDRATINIB
CHEMBL1287853
 2019
ENTRECTINIB
CHEMBL1983268
 2019
ZANUBRUTINIB
CHEMBL3936761
 2019
NERATINIB
CHEMBL180022
 2017
BRIGATINIB
CHEMBL3545311
 2017
ACALABRUTINIB
CHEMBL3707348
 2017
OLMUTINIB
CHEMBL3786343
 2016
OSIMERTINIB
CHEMBL3353410
 2015
NINTEDANIB
CHEMBL502835
 2014
IBRUTINIB
CHEMBL1873475
 2013
BOSUTINIB
CHEMBL288441
 2012
DASATINIB
CHEMBL5416410
 2006
MITOXANTRONE
CHEMBL58
 1987
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:41:48Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5251